Metabolic bone disease in patients with liver disease

Current Gastroenterology Reports

Volumn 5, Issue 1, 2003, Pages 71-77

  Carey, Elizabeth ^b   Balan, Vijayan ^a  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; CORTICOSTEROID; DEOXYPYRIDINOLINE; ESTROGEN; ETIDRONIC ACID; FLUORIDE SODIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYPROLINE; PREDNISOLONE; PYRIDINOLINE; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN C; TESTOSTERONE; VITAMIN D;

COMORBIDITY; CORTICOSTEROID INDUCED OSTEOPOROSIS; ESOPHAGITIS; ESOPHAGUS ULCER; ESOPHAGUS VARICES BLEEDING; ESTROGEN DEFICIENCY; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GENETIC POLYMORPHISM; HUMAN; HYPOGONADISM; LIVER DISEASE; LIVER TOXICITY; MALABSORPTION; METABOLIC BONE DISEASE; OSTEOLYSIS; OSTEOPENIA; PATHOGENESIS; REVIEW; RISK FACTOR; STOMACH ULCER; VITAMIN D DEFICIENCY; PATHOPHYSIOLOGY;

BONE DISEASES, METABOLIC; HUMANS; LIVER DISEASES; RISK FACTORS;

EID: 0037607647     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-003-0012-z     Document Type: Review

References (51)

1. Hughes DE, Dai A, Tiffee JC, et al.: Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med 1996, 2:1132-1136.
2. Gallego-Rojo FJ, Gonzalez-Calvin JL, Munoz-Torres M, et al.: Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology 1998, 28:695-699.
3. Hattori N, Kurahachi H, Ikekubo K, et al.: Serum growth hormone-binding protein, insulin-like growth factor-I, and growth hormone in patients with liver cirrhosis. Metab Clin Exper 1992, 41:377-381.
4. Janes CH, Dickson ER, Okazaki R, et al.: Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest 1995, 95:2581-2586.
5. Guanabens N, Pares A, Marinoso L, et al.: Factors influencing the development of metabolic bone disease in primary biliary cirrhosis. Am J Gastroenterol 1990, 85:1356-1362.
6. Hodgson S, Dickson E, Wahner H, et al.: Bone loss and reduced osteoblast function in primary biliary cirrhosis. Ann Intern Med 1985, 103:855-860.
7. Duarte MP, Farias ML, Coelho HS, et al.: Calcium-parathyroid hormone-vitamin D axis and metabolic bone disease in chronic viral liver disease. J Gastroenterol Hepatol 2001, 16:1022-1027.
8. Lindor KD, Jorgensen RA, Tiegs RD, et al.: Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial. J Hepatol 2000, 33:878-882.
9. Guanabens N, Pares A, Alvarez L, et al.: Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis. J Bone Miner Res 1998, 13:731-738.
10. Hay JE, Lindor KD, Wiesner RH, et al.: The metabolic bone disease of primary sclerosing cholangitis. Hepatology 1991, 14:257-261.
11. Matloff D, Kaplan M, Neer R, et al.: Osteoporsis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment. Gastroenteroogy 1981, 83:97-102.
12. Herlong H, Becker R, Maddrey W: Bone disease in primary biliary cirrhosis: histologic features and response to 25-hydroxyvitamin D. Gastroenterology 1982, 83:103-108.
13. Gong G, Stern H, Cheng S, et al.: The association of bone mineral density with vitamin d receptor gene polymorphisms. Osteoporos Int 1999, 9:55-64.
14. Pares A, Guanabens N, Alvarez L, et al.: Collagen type Ialpha 1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis. Hepatology 2001, 33:554-560.
15. Springer JE, Cole DE, Rubin LA, et al.: Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. Gastroenterology 2000, 118:145-51.
16. Guardiola J, Xiol X, Sallie R, et al.: Influence of the vitamin D receptor gene polymorphism on bone loss in men after liver transplantation. Ann Intern Med 1999, 131:752-755.
17. Hay JE: Vitamin D receptor polymorphism and posttransplantation bone loss. Liver Transpl 2001, 7:68-69.
18. Bell H, Raknerud N, Falch J, Haug E: Inappropriately low levels of gonadotrophins in amenorrhoeic women with alcoholic and non-alcoholic cirrhosis. Eur J Endocrinol 1995, 132:444-449.
19. Turner R: Skeletal response to alcohol. Alcohol Clin Exp Res 2000, 24:1693-1701.
20. Mitchison H, Malcolm A, Bassendine M, James O: Metabolic bone disease in primary biliary cirrhosis at presentation. Gastroenterology 1988, 94:463-470.
21. Porayko MK, Wiesner RH, Hay JE, et al.: Bone disease in liver transplant recipients: incidence, timing, and risk factors. Transplant Proc 1991, 23:1462-1465.
22. Eastell R, Dickson ER, Hodgson SE et al.: Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology 1991, 14:296-300.
23. Camisasca M, Crosignani A, Battezzati P: Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis. Hepatology 1994, 20:633-637.
24. Ormarsdottir S, Ljunggren O, Mallmin H, et al.: Low body mass index and use of corticosteroids, but not cholestasis, are risk factors for osteoporosis in patients with chronic liver disease. J Hepatol 1999, 31:84-90.
25. Angulo P, Therneau TM, Jorgensen A, et al.: Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression. J Hepatol 1998, 29:729-735.
26. Corazza G, Trevisani F, Di Stefano M, et al.: Early increase of bone resorption in patients with liver cirrhosis secondary to viral hepatitis. Dig Dis Sci 2000, 45:1392-1399.
27. Chen C, Wang S, Jeng F, Lee S: Metabolic bone disease of liver cirrhosis: is it a parallel to the clinical severity of cirrhosis? J Gastroenterol Hepatol 1996, 11:417-421.
28. Solis-Herruzo J, Castellano G, Fernandez I, et al.: Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C. J Hepatol 2000, 33:812-817.
29. Trautwein C, Possienke M, Schlitt H, et al.: Bone density and metabolism in patients with viral hepatitis and cholestatic liver diseases before and after liver transplantation. Am J Gastroenterol 2000, 95:2343-2351.
30. Carey EJ, Balan V, Kremers WK, Hay JE: Osteopenia and fracturing in hepatitis C and alcoholic liver disease: not just a cholestatic problem [abstract]. Gastroenterology 2002, 122:A531.
31. Peris P, Guanabens N, Pares A, et al.: Vertebral fractures and osteopenia in chronic alcoholic patients. Calcif Tissue Int 1995, 57:111-114.
32. Peris P, Pares A, Guanabens N, et al.: Reduced spinal and femoral bone mass and deranged bone mineral metabolism in chronic alcoholics. Alcohol Alcohol 1992, 27:619-625.
33. Rubin E, Caballeria J, Rodes J, Munoz J: Vertebral fractures and osteopenia in chronic alcoholic patients. Calcif Tissue Int 1995, 57:111-114.
34. Bikle DD, Stesin A, Halloran B, et al.: Alcohol-induced bone disease: relationship to age and parathyroid hormone levels. Alcohol Clin Exp Res 1993, 17:690-695.
35. Schnitzler CM, Solomon L: Bone changes after alcohol abuse. South Afr Med J 1984, 66:730-734.
36. Siris E, Miller P, Barrett-Connor E, et al.: Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women. JAMA 2001, 286:2815-2822.
37. Felson D, Zhang Y, Hannan M, et al.: Alcohol intake and bone mineral density in elderly men and women. The Framingham Study. Am J Epidemiol 1995, 142:485-492.
38. Santolaria F, Gonzalez-Reimers E, et al.: Osteopenia assessed by body composition analysis is related to malnutrition in alcoholic patients. Alcohol 2000, 22:147-157.
39. Epstein O, Kato Y, Dick R, Sherlock S: Vitamin D, hydroxyapatite, and calcium gluconate in treatment of cortical bone thinning in postmenopausal women with primary biliary cirrhosis. Am J Clin Nutr 1982, 36:426-430.
40. Matloff DS, Kaplan MM, Neer RM, et al.: Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment. Gastroenterology 1982, 83:97-102.
41. Crippin J, Jorgensen R, Dickson E, Lindor K: Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment. Am J Gastroenterol 1994, 89:47-50.
42. Collier JD, Ninkovic M, Compston JE: Guidelines on the management of osteoporosis associated with chronic liver disease. Gut 2002, 50:1-9.
43. Shiomi S, Masaki K, Habu D, et al.: Calcitriol for bone disease in patients with cirrhosis of the liver. J Gastroenterol Hepatol 1999, 14:547-552.
44. Olsson R, Mattsson L, Obrant K, Mellstrom D: Estrogen-progestogen therapy for low bone mineral density in primary biliary cirrhosis. Liver 1999, 19:188-192.
45. Floreani A, Zappala F, Fries W, et al.: A 3-year pilot study with 1,25-dihydroxyvitamin D, calcium, and calcitonin for severe osteodystrophy in primary biliary cirrhosis. J Clin Gastroenterol 1997, 24:239-244.
46. Hay J, Malinchoc M, Dickson R: A controlled trial of calcitonin therapy for the prevention of post-liver transplantation atraumatic fractures in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 2001, 34:292-298.
47. Wolfhagen F, van Buuren H, den Ouden J, et al.: Cyclical etidronate in the prevention of bone los in corticosteroid-treated primary biliary cirrhosis: a prospective, controlled pilot study. J Hepatol 1997, 26:325-330.
48. Guanabens N, Farrerons J, Perez-Edo L, et al.: Cyclical etidronate versus sodium fluoride in established postmenopausal osteoporosis: a randomized 3 year trial. Bone 2000, 27:123-128.
49. Pares A, Guanabens N, Ros I, et al.: Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis [abstract]. Hepatology 1999, 30:472A.
50. Neer RM, Arnaud CD, Zanchetta JR, et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
51. Guanabens N, Pares A, del Rio L, et al.: Sodium fluoride prevents bone loss in primary biliary cirrhosis. J Hepatol 1992, 15:345-349.